Your browser doesn't support javascript.
loading
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA).
Di Nardo, P; Basile, D; Siciliano, A; Pelizzari, G; Corvaja, C; Buriolla, S; Ongaro, E; Maria Grazia, D; Garattini, S K; Foltran, L; Guardascione, M; Casagrande, M; Buonadonna, A; Prantera, T; Aprile, G; Puglisi, F.
Afiliação
  • Di Nardo P; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy.
  • Basile D; Unit of Medical Oncology, Lamezia Terme Hospital, Italy. Electronic address: deborabasile1090@gmail.com.
  • Siciliano A; Unit of Medical Oncology, AO Pugliese-Ciaccio of Catanzaro, Italy.
  • Pelizzari G; Department of Oncology, University Hospital of Udine, Italy.
  • Corvaja C; Department of Medicine, University of Udine, Udine, Italy.
  • Buriolla S; Department of Medicine, University of Udine, Udine, Italy.
  • Ongaro E; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy.
  • Maria Grazia D; Unit of Medical Oncology, Lamezia Terme Hospital, Italy.
  • Garattini SK; Department of Oncology, University Hospital of Udine, Italy.
  • Foltran L; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy.
  • Guardascione M; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy.
  • Casagrande M; Department of Oncology, University Hospital of Udine, Italy.
  • Buonadonna A; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy.
  • Prantera T; Unit of Medical Oncology, Lamezia Terme Hospital, Italy.
  • Aprile G; Medical Oncology, ULSS 8 Berica, Vicenza, Italy.
  • Puglisi F; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy; Department of Medicine, University of Udine, Udine, Italy.
Dig Liver Dis ; 2023 Aug 14.
Article em En | MEDLINE | ID: mdl-37586908
BACKGROUND: The optimal strategy for second-line (IIL) treatment in KRAS wt metastatic colorectal cancer (mCRC) is not determined yet. METHODS: A random-effect NMA of phase II/III RCTs was conducted to evaluate IIL treatment for all-RAS wt mCRC, comparing anti-EGFR or anti-VEGF, and chemotherapy (CT). RESULTS: Overall, 11 RCTs (3613 patients) were included. In KRAS wt patients, PFS was improved with anti-VEGF (HR 0.43) and anti-EGFR (HR 0.63) vs CT. However, anti-VEGF based therapy had the highest likelihood of being ranked as the best treatment in terms of PFS (SUCRA 99.3%) and OS (SUCRA 99.4%). Bevacizumab-based treatment is most likely to be the best treatment in terms of PFS (SUCRA 89.1%) and OS (SUCRA 86.7%). CONCLUSIONS: Second line treatment with anti-VEGF and anti-EGFR improved PFS in mCRC patients, however, anti-VEGF based therapy, particularly CT plus bevacizumab, is the best treatment according to SUCRA in terms of PFS and OS.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article